MENU
ENTO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Entero Therapeutics (ENTO) Ownership - Who owns Entero Therapeutics?
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
2.2M
P/E Ratio
0.03
Total Cash
59.35K
Projected Growth
N/A
Total Debt
835.61K
Revenue
N/A
Risk (Beta)
0.49
Dividend Yield
N/A
Total Cash/Share
0.01
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
ENTO
Capitalization
2.2M
P/E Ratio
0.03
Risk (Beta)
0.49
Dividend Yield
N/A
Total Cash
59.4K
Total Cash/Share
0.01
Total Debt
836K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
-5.22M
P/B Ratio
0.29
Cash Flow
N/A
Earnings
-8.73
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
477
Current Ratio
2.90
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-7.42M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-28.52
Shares Held By Institutions
63.2K
Shares Outstanding - Current
4.77M
Total Liabilities
28.7M
Total Volume MTD
N/A
Value
1
Gain YTD
-25.707
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information